Efficacy and safety of onceweekly semaglutide versus exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3). - Hramiak, I; Ahmann, A; Capehorn, M (Can J Diabetes, 2016)
(Suppl. 1) Abstract